Evidence map›Paper›PMID 32798563›Full record

ArticleAmerican journal of kidney diseases : the official journal of the National Kidney Foundation2021

Adiposity, Physical Function, and Their Associations With Insulin Resistance, Inflammation, and Adipokines in CKD.

Sankar D Navaneethan, John P Kirwan, Erick M Remer, Erika Schneider, Bryan Addeman, Susana Arrigain, Ed Horwitz, Jeffrey C Fink, James P Lash, Charles A McKenzie and 8 more

Open access · bronzeAbstract read
In one paragraph

Article in American journal of kidney diseases : the official journal of the National Kidney Foundation, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 26 papers.

0numbers the graph read from it
0cells of the map it votes in
26citing papers in PubMed
3.2field-weighted citation impact, top 7% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

26 citing papers in PubMed, 49 citations in OpenAlex.

  1. Trial
  2. Article
  3. Article
  4. Article
  5. Article
  6. Article
  7. Article
  8. Article
  9. Article
  10. Article
  11. Review
  12. Article
  13. Article
  14. Article
  15. Review
  16. Article
  17. Article
  18. Nesfatin-1 - as a diagnosis regulatory peptide in type 2 diabetes mellitus.Journal of diabetes and metabolic disorders · 2022
    Article
  19. Article
  20. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

18 authors at 11 institutions in 2 countries.

Sankar D NavaneethanSection of Nephrology, Department of Medicine, Baylor University College of Medicine, Houston, TX; Section of Nephrology, Michael E. DeBakey Veterans Affairs Medical Center, Houston, TX; Institute of Clinical and Translational Research, Baylor College of Medicine, Houston, TX. Electronic address: sankar.navaneethan@bcm.edu.
John P KirwanIntegrated Physiology and Molecular Medicine, Pennington Biomedical Research Center, Baton Rouge, LA.
Erick M RemerImaging Institute, Cleveland Clinic Foundation, Cleveland, OH.
Erika SchneiderImaging Institute, Cleveland Clinic Foundation, Cleveland, OH.
Bryan AddemanCanatomical Services, Toronto, Ontario, Canada.
Susana ArrigainDepartment of Quantitative Health Sciences, Cleveland Clinic, Cleveland, OH.
Ed HorwitzDepartment of Nephrology, MetroHealth Medical Center, Cleveland, OH.
Jeffrey C FinkDepartment of Medicine, University of Maryland School of Medicine, Baltimore, MD.
James P LashDivision of Nephrology, Department of Medicine, University of Illinois at Chicago College of Medicine, Chicago, IL.
Charles A McKenzieCanatomical Services, Toronto, Ontario, Canada; Department of Medical Biophysics, University of Western Ontario, London, Ontario, Canada.
Mahboob RahmanDivision of Nephrology and Hypertension, Department of Medicine, Case Western Reserve University School of Medicine, Cleveland, OH.
Panduranga S RaoDivision of Nephrology, Department of Internal Medicine, University of Michigan Medical School, Ann Arbor, MI.
Jesse D ScholdDepartment of Quantitative Health Sciences, Cleveland Clinic, Cleveland, OH; Center for Populations Health Research, Lerner Research Institute, Cleveland Clinic, Cleveland, OH.
Tariq ShafiDepartment of Medicine, University of Mississippi Medical Center, Jackson, MS.
Jonathan J TaliercioDepartment of Nephrology and Hypertension, Cleveland Clinic, Cleveland, OH.
Raymond R TownsendRenal, Electrolyte, and Hypertension Division, Department of Medicine, University of Pennsylvania Perelman School of Medicine, Philadelphia, PA.
Harold I FeldmanRenal, Electrolyte, and Hypertension Division, Department of Medicine, University of Pennsylvania Perelman School of Medicine, Philadelphia, PA; Department of Biostatistics, Epidemiology and Informatics, University of Pennsylvania Perelman School of Medicine, Philadelphia, PA; Center for Clinical Epidemiology and Biostatistics, University of Pennsylvania Perelman School of Medicine, Philadelphia, PA; Welch Center for Prevention, Epidemiology, and Clinical Research, Johns Hopkins University, Baltimore, MD.
CRIC Study Investigators
Cleveland Clinic · USUniversity of Pennsylvania · USBaylor University · USCase Western Reserve University · USMetroHealth Medical Center · USPennington Biomedical Research Center · USUniversity of Illinois Chicago · USUniversity of Maryland, Baltimore · USUniversity of Michigan–Ann Arbor · USUniversity of Mississippi Medical Center · USWestern University · CA

Funding

UCSF CLINICAL AND TRANSLATIONAL SCIENCE INSTITUTEUL1RR024131 · NCRR · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · PI JOHNSTON, S. CLAIBORNE · 2006 to 2011
$111.2M
Tracking & Evaluation CoreU54GM104940 · NIGMS · LSU PENNINGTON BIOMEDICAL RESEARCH CTR · PI Leigh Lamonica · 2012 to 2026
$69.1M
Scientific and Data Coordinating Center(SDCC) for the P*U01DK060990 · NIDDK · UNIVERSITY OF PENNSYLVANIA · PI FELDMAN, HAROLD I · 2001 to 2017
$50.1M
Clinical and Translational Science Collaborative of ClevelandUL1TR000439 · NCATS · CASE WESTERN RESERVE UNIVERSITY · PI KONSTAN, MICHAEL W. · 2012 to 2016
$50.0M
Michigan Institute for Clinical and Health Research (MCHR)UL1TR000433 · NCATS · UNIVERSITY OF MICHIGAN AT ANN ARBOR · PI MASHOUR, GEORGE ALEXANDER · 2012 to 2016
$49.9M
Institutional Clinical and Translational Science AwardUL1TR000003 · NCATS · UNIVERSITY OF PENNSYLVANIA · PI FITZGERALD, GARRET A · 2012 to 2015
$38.9M
Clinical and Translational Science Collaborative of ClevelandUL1TR002548 · NCATS · CASE WESTERN RESERVE UNIVERSITY · PI MCCOMSEY, GRACE A · 2018 to 2022
$35.5M
Role of obesity in preeclamptic pregnancy.P20GM121334 · NIGMS · UNIVERSITY OF MISSISSIPPI MED CTR · PI Babbette LaMarca, Jane F Reckelhoff · 2017 to 2026
$26.4M
Tulane COBRE in Cardiometabolic Diseases Clinical Research CoreP20GM109036 · NIGMS · TULANE UNIVERSITY OF LOUISIANA · PI Ning Liu · 2016 to 2026
$25.3M
Continuation of the Coordinating Center for the Chronic Renal Insufficiency Cohort (CRIC) StudyU24DK060990 · NIDDK · UNIVERSITY OF PENNSYLVANIA · PI Amanda Hyre Anderson, Laura M Dember · 2018 to 2026
$21.5M
Zonulin Antibodies in Intestinal Permeabilitiy in IDDMM01RR016500 · NCRR · UNIVERSITY OF MARYLAND BALTIMORE · PI ONUKWUGHA, EBERECHUKWU · 2002 to 2009
$20.2M
Study of the Care and Outcomes of REnal InsufficiencyU01DK060902 · NIDDK · KAISER FOUNDATION RESEARCH INSTITUTE · PI GO, ALAN S · 2001 to 2025
$19.5M
NCATS NIH HHS UL1 TR000003NCATS NIH HHS UL1 TR000424NCATS NIH HHS UL1 TR000433NCATS NIH HHS UL1 TR000439NCATS NIH HHS UL1 TR002548NCRR NIH HHS M01 RR016500NCRR NIH HHS UL1 RR024131NCRR NIH HHS UL1 RR029879NIDDK NIH HHS R01 DK101500NIDDK NIH HHS R01 DK119199NIDDK NIH HHS R01 DK139225NIDDK NIH HHS R21 DK130018NIDDK NIH HHS U01 DK060902NIDDK NIH HHS U01 DK060963NIDDK NIH HHS U01 DK060980NIDDK NIH HHS U01 DK060984NIDDK NIH HHS U01 DK060990NIDDK NIH HHS U01 DK061021NIDDK NIH HHS U01 DK061022NIDDK NIH HHS U01 DK061028NIDDK NIH HHS U24 DK060990NIGMS NIH HHS P20 GM109036NIGMS NIH HHS P20 GM121334NIGMS NIH HHS U54 GM104940
6 · The paper itself

Abstract

RATIONALE &

objectivesAdiposity and physical fitness levels are major drivers of cardiometabolic risk, but these relationships have not been well-characterized in chronic kidney disease (CKD). We examined the associations of visceral adipose tissue (VAT), subcutaneous adipose tissue (SAT), intrahepatic fat, and physical function with inflammation, insulin resistance, and adipokine levels in patients with CKD. STUDY

designProspective cohort study. SETTING &

participantsParticipants with stages 3-5 CKD not receiving maintenance dialysis, followed up at one of 8 clinical sites in the Chronic Renal Insufficiency Cohort (CRIC) Study, and who underwent magnetic resonance imaging of the abdomen at an annual CRIC Study visit (n = 419). PREDICTORS: VAT volume, SAT volume, intrahepatic fat, body mass index, waist circumference, and time taken to complete the 400-m walk test (physical function). OUTCOMES: Markers of inflammation (interleukin 1β [IL-1β], IL-6, tumor necrosis factor receptor 1 [TNFR1], and TNFR2), insulin resistance (homeostasis model assessment of insulin resistance), and adipokine levels (adiponectin, total and high molecular weight, resistin, and leptin). ANALYTICAL APPROACH: Multivariable linear regression of VAT and SAT volume, intrahepatic fat, and physical function with individual markers (log-transformed values), adjusting for relevant covariates.

resultsMean age of the study population was 64.3 years; 41% were women, and mean estimated glomerular filtration rate was 53.2±14.6 (SD) mL/min/1.73m LIMITATIONS: Lack of longitudinal data and dietary details.

conclusionsVarious measures of adiposity are associated with cardiometabolic risk factors. Physical function was also associated with the cardiometabolic risk factors studied and does not modify associations between fat measures and cardiometabolic risk factors. Longitudinal studies of the relationship between body fat and aerobic fitness with cardiovascular and kidney disease progression are warranted.

Indexed as

Abdominal FatInsulin ResistancePhysical Functional PerformanceRenal Insufficiency, ChronicBiomarkersBody Mass IndexCardiometabolic Risk FactorsCohort StudiesDisease ProgressionFemaleHumansImmunologic FactorsInflammationMaleMiddle AgedRisk AssessmentBiomarkersImmunologic Factorsabdominal fatadipose tissuebody mass index (BMI)cardiometabolic risk factorcardiovascular diseasechronic kidney disease (CKD)fatfat distributionObesityoverweightphysical functionrenal dysfunctionsubcutaneous fat

Identifiers

PMID32798563
PMCPMC7752817
OpenAlexW3048756775

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.